

RESEARCH ARTICLE

Open Access

N-heteroatom substitution effect in 3-aza-cope rearrangements

Mário JS Gomes^{1,2}, Luis FV Pinto¹, Paulo MC Glória¹, Henry S Rzepa^{3†}, Sundaresan Prabhakar^{1†} and Ana M Lobo^{1*†}

Abstract

Background: The nature of the heteroatom substitution in the nitrogen of a 3-aza-Cope system is explored.

Results: While N-propargyl isoxazolin-5-ones suffer 3-aza-Cope rearrangements at 60°C, the corresponding N-propargyl pyrazol-5-ones need a higher temperature of 180°C for the equivalent reaction. When the propargyl group is substituted by an allyl group, the temperature of the rearrangement for both type of compounds is less affected by the nature of the heteroatom present. Treatment with a base, such as ethoxide, facilitates the rearrangement, and in the case of isoxazolin-5-ones other ring opening reactions take precedence, involving N–O ring cleavage of the 5-membered ring. However when base-catalysed decomposition is prevented by substituents, products arising from a room temperature aza-Cope rearrangement are isolated. A possible mechanistic pathway based on free energies derived from density functional calculations involving cyclic intermediates is proposed.

Conclusions: The nature of the heteroatom substitution in the nitrogen of a 3-aza-Cope system leads to a remarkable difference in the energy of activation of the reaction.

Background

Cope-type rearrangements constitute a highly efficient means for carbon–carbon bond formation, offering high regio- and stereocontrol which renders them especially useful in synthesis [1]. The Aza-Cope rearrangement in particular has some advantages over its oxo-counterpart, namely the fine tuning of the reaction temperature which can be achieved by attaching different substituents to the nitrogen of the rearranging system [2-5], by adding charges or by encapsulating it [6]. As previously reported by us appropriately substituted *N*-alkyl(silyl)oxy-*N*-allyl enamines undergo smooth 3,3-sigmatropic rearrangements to the corresponding *N*-alkyl(silyl)oxy imino ethers in good to excellent yields [7]. Theoretical studies also indicate that an oxyanionic substituent on the nitrogen atom reduces substantially the activation energies for these rearrangements [8]. We report in this manuscript the results obtained with the *N*-propargyl and *N*-allyl 5-membered heterocycles, pyrazolin-5-ones

and isoxazolin-5-ones, either under thermolysis or in the presence of a base.

Results and discussion

The required compounds **1** for the rearrangement studies were obtained by alkylation of **3** using a Mitsunobu reaction [9] as in Scheme 1. The isolated compounds **1** and **2** were easily separated by chromatography (cf. Experimental). Heating either **1** or **2** gave rise to a 3,3-sigmatropic rearrangement [5,10] and the same final compound **4** as in Scheme 1 (Table 1, entries 1–4).


In the presence of EtOK and 18-crown-6 ether at r.t., it was found that the propargyl group of **1a** isomerized to the corresponding allene **5a** as in Scheme 2, which could in turn suffer upon heating a 3,3-sigmatropic rearrangement leading to **6a**. This last compound could also be reached from **2a** by treatment with base to give **7a**, followed by thermolysis. Thus coupling of these two reactions opened the way to 3 isomeric compounds of **1a**. It is worth noticing that, while the *N*-allyl **5a** (Table 1, entry 5) reacts in a similar way to the *N*-propargyl **1a** (entry 1) in the 3-aza-Cope rearrangement, the corresponding *O*-allyl **7a** (entry 6) and the *O*-propargyl **2a** (entry 3) rearrange faster and give better yields. Similar results are found for the pair **1a/2a** and

* Correspondence: aml@fct.unl.pt

†Equal contributors

¹Chemistry Department, REQUIMTE/CQFB, FCT, Universidade Nova de Lisboa, 2829-516, Caparica, Portugal

Full list of author information is available at the end of the article



Scheme 1 Synthesis and thermal rearrangement of *N*-propargyl pyrazolin-5-ones **1** and their isomers **2**.

1b/2b. The reason is probably related to the more facile nature of the 3-oxa-Cope (Claisen) *versus* the 3-aza-Cope rearrangements [3].

Next, the *N*-propargyl isoxazolinones **8a,b** and the *N*-allyl **8c,d** [11] were synthesised (cf. Experimental) and heated to give the corresponding rearranged compounds, the allenes **9a,b**, (Scheme 3, Table 2, entries 1,2) and the allyl **9c,d** (Scheme 4, Table 2, entries 3,4). It was found that the first ones required a much lower temperature for the rearrangement.

The synthesis of **8e** is depicted in Scheme 5 as well as its product after heating (Table 2, entry 5). Desilylation [12] of compound **10** yielded the corresponding enehydroxylamine **11**, which was found to be unstable and to lactonise spontaneously to the 2-allyl-isoxazolone **8e** (Scheme 5). The latter on thermolysis (180°C) furnished 2-cyano-pent-4-enoic acid ethyl ester **12**, as shown. In this case the thermodynamic gain resulting from the loss of carbon dioxide from the rearranged product **9e** is also accompanied by the formation of the cyano derivative **12** [13]. When treated with potassium ethoxide, **8e** led to the formation of *N*-allyl-malonamic acid ethyl ester **13** instead of the rearranged product (Scheme 6).

Table 1 Rearrangements of pyrazolin-5-ones **1** and their isomers **2**


#	Pyrazolinones 1 & isomers 2	Conditions temp./ time	Products yield ^a (%)
1	1a : R = Me	180°C / 60 m	4a : R = Me (35)
2	1b : R = Ph	180°C / 10 m	4b : R = Ph (72)
3	2a : R = Me	180°C / 10 m	4a : R = Me (90)
4	2b : R = Ph	180°C / 10 m	4b : R = Ph (99)
5	5a : R = Me	180°C / 30 m	6a : R = Me (30)
6	7a : R = Me	180°C / 10 m	6a : R = Me (80)

^aIsolated yields after flash-chromatography.

Again loss of carbon dioxide, as found earlier by Woodman [14], occurred with a rearrangement possibly involving cyclic intermediates to provide the amide group of **13** [15]. The energetics of possible mechanistic pathways for this process were explored using a density functional approach (ω B97XD functional, 6-311G(d,p) basis set and SCRF(CPCM) continuum solvation method for ethanol as a model polar solvent). The reaction is sufficiently complex that a significant number of possible mechanistic pathways can be envisaged using the classical "arrow pushing" approach. Here we adopt the approach of incrementally locating pathways to the product and optimizing them for the lowest overall activation free energy. Such an approach of course does not guarantee finding the global energetic minimum in mechanistic pathways. Instead the objective is to find a thermally reasonable pathway that might approximately correspond to the observed rate of the reaction, and along the way eliminating pathways that have unreasonably high activation free energies.

The mechanistic exploration is set out in Scheme 6. The first route explored involved **8e** and ethoxide anion acting as a nucleophile. Addition of the ethoxide gives **8e-1** as the first intermediate, followed by ring closure to **8e-2** [16]. The most direct route (Occam's razor) to **13** is by a dyotropic rearrangement of **8e-2** to **8e-3**, followed by protonation and decarboxylation. The energetic high point of this pathway is the transition state for the dyotropic rearrangement of the intermediate oxaziridine (**8e-TS1**) which manifests as unreasonably high (Additional file 1: Table S1, entry 4) ^a.

The next route explored was with ethoxide acting as a base, abstracting the allylic proton to give the intermediate **8e-4**. A ring closure to **8e-5**, followed by 1,3 intramolecular proton transfer to give **8e-6**, a second proton transfer to reform alkoxide anion and final ring opening to **8e-7** gives **8e-8**, which is merely a tautomer of **8e-3** and can decarboxylate as before to give **13**. The



Scheme 2 Thermal and base catalyzed rearrangements of pyrazolin-5-ones and their isomers.

high point of this pathway is **8e-TS2**, which shows as an entirely reasonable barrier for the reaction (Additional file 1: Table S1, entry 5). Whilst this does not constitute a formal mechanistic proof of the reaction, it does imply a reasonable one, and further that any alternative mechanism must have an overall lower energy barrier than this one.

Whereas it is traditional, indeed conventional, for the mechanism of a synthetic pathway to be speculated upon using mechanistic reaction arrows, we suggest here that increasingly such speculations must be supported by a computational exploration of the potential free energy surface. In this case, this has been done with a procedure which, including as it does dispersion corrections for all species, a triple-zeta quality basis with polarization functions, and a correction for continuum solvation, is suggested to be the minimum in quality appropriate for such exploration.

Exposure of 2-allyl-3,4-diphenyl-isoxazolin-5-one (**8d**) to similar conditions gave rise after 10 minutes to **14** in 25% yield (along with desoxybenzoin in 45%, Scheme 7) with no 3-aza-Cope rearrangement being observed. Compound **14** was found to generate desoxybenzoin (**15** **R = H**) by quenching under aqueous acidic conditions. Quenching the reaction with deuterated acetic acid (CH_3COOD) resulted in the isolation of monodeuterated


benzoin (**15** **R = D**). A possible mechanism is shown and follows along equivalent intermediates, **8d-3** or the oxaziridine derived **8d-4** [17], until reaching **8d-5**. A phenyl substituent on carbon 3 in the β -lactone ring of **8d-5** now leads instead to **14**.

Substrate **8b**, where formation of the carbanion adjacent to the ring nitrogen of the oxazolidinone is blocked by substitution, was next treated with potassium ethoxide (0.1 eq), in the presence of 18-crown-6 ether, at room temperature (5 days), and gave rise to **9b** in 55% yield (cf. Scheme 8). Here the opening of the five membered ring leading to **8b-1** might lower the energy of the reaction either by allowing an easier access to the conformation leading to the transition state or by anionic charge acceleration of the rearrangement. The importance of EtOK was noticed further when, after 5 days at r. t., in its absence, the rearrangement of **8b** was observed to occur, but in a much lower yield (<10%). The same compound treated with LDA or *tert*-BuLi, in the


Table 2 Thermolysis of isoxazolin-5-ones **8** in the presence and absence of potassium ethoxide

#	Compounds 8	Conditions	Products Yield ^a (%)	
			9	Others
1	8a : R = H	60°C / 30 m	9a (75)	-
2	8b : R = Me	60°C / 10 m	9b (85)	-
3	8c : R' = Me	180°C / 7 h	9c (95) ^b	-
4	8d : R' = Ph	180°C / 5 h	9d (97)	-
5	8e	180°C / 5 h	-	12 (80)
6	8e	EtOK ^{c,d} / RT / 5 h	-	13 (80)
7	8d : R' = Ph	EtOK ^{c,d} / RT / 10 m	-	14 (25) 15 (45)
8	8b : R = Me	EtOK ^{c,e} / RT / 5 d	9b (55)	-
		EtOK ^{c,d} / RT / 10 m	9b (30)	-

^aIsolated yields after flash-chromatography. ^bSee ref. 11. ^cIn the presence of 18-crown-6 ether. ^dIn the presence of EtOK (1.5 eq). ^eIn the presence of EtOK (0.1 eq).




Scheme 3 3-Aza-Cope rearrangement of *N*-propargyl isoxazolin-5-ones **8a,b**.



presence of 12-crown-6 ether and in the same conditions of concentration and temperature, showed no reaction. Thus the anion derived from the possible base removal of the terminal triple bond proton does not appear to accelerate the rearrangement, but the oxyanion formed upon the isoxazolidinone ring opening did have a moderately positive effect enabling the rearrangement to occur at room temperature.

Conclusions

In conclusion: 1) substitution of the nitrogen-1 of pyrazolin-5-ones by oxygen lowers the temperature of the 3-aza-Cope rearrangement of isoxazolin-5-ones vis-à-vis the corresponding pyrazolin-5-ones when the rearranging element includes a propargyl group attached to the heterocyclic nitrogen-2; 2) when the propargyl group is replaced by an allyl group the rearranging temperature is higher and similar in both compounds; 3) treatment with potassium ethoxide as base in the presence of 12-crown-6 ether at room temperature, while leaving the pyrazolin-5-one heterocycle untouched, leads to ring opening of



isoxazolin-5-ones, followed by further reactions. The putative oxaziridine or other cyclic intermediate then suffer base catalysed ring opening reaction whenever there are protons available in the carbon α to the ring nitrogen, leading to a 6-membered aza,oxa-ring system. When such position is blocked by substituents the 3-aza-Cope rearrangement occurs at room temperature.

Experimental


General

Melting points were determined on a Reichert Thermovar apparatus and are uncorrected. Ordinary mass spectra were recorded on a Fisons TRIO 2000 or AEI MS-9 spectrometer. High-resolution MS spectra (HRMS) were obtained on a FT-ICR/MS Finnigan FT/MS 2001-DT spectrometer at 70 eV by electron impact or on a Finnigan MAT 900 ST spectrometer by ESI. Infrared (IR) spectra were recorded on a Perkin-Elmer 1000X FT-IR spectrometer. Proton and ¹³C NMR spectra were recorded in CDCl₃ on a Bruker ARX 400 spectrometer (400 MHz for ¹H, 100.63 MHz for ¹³C). Chemical shifts are reported relative to tetramethylsilane as the internal reference (δ_{H} 0.00) for ¹H NMR spectra and to CDCl₃ (δ_{C} 77.00) for ¹³C NMR spectra. IR spectra were run on an FT Perkin-Elmer 1000 instrument, with absorption frequencies expressed in reciprocal centimeters. Thin-layer chromatography was performed on Merck silica gel 60 F₂₅₄ 0.2 mm thick plates, visualized under UV light or by exposing to iodine vapour. For preparative separations the plates were 0.5–1 mm thick. For flash chromatography silica Merck Kieselgel 60, 70–230 mesh was used. Usual work-up implies drying the water- or brine-washed organic extracts over anhydrous sodium sulfate or magnesium sulfate, followed by filtration and solvent removal under reduced pressure. Anhydrous solvents were dried and freshly distilled by standard methods [18].

Synthesis of starting materials

Ethyl 3-oxo-2-phenyl-butanoate

To a solution of ethyl acetoacetate (1.5 g, 11.5 mmol) in CH₂Cl₂ (45 mL), was added triphenylbismuth carbonate [19] (6.33 g, 12.6 mmol). After being stirred under argon for 24 h at 40°C, the mixture was filtered and concentrated at reduced pressure. The crude was purified by CC (silica; Et₂O / *n*-hexane 1:3) to give the title compound as a yellow oil [20] (1.44 g, 61%): IR (NaCl) ν_{max} (cm⁻¹): 3063, 2983, 1745 (C=O, ester), 1721 (C=O, ketone). ¹H NMR (400 MHz CDCl₃) *keto-enol* equilibrium, *enol* (55%): δ 1.18 (3H, t, *J* = 7.2 Hz, OCH₂CH₃), 1.85 (3H, s, CH₃CO), 4.23 (2H, m, OCH₂CH₃), 7.14–7.38 (5H, m, Ar-H), 13.13 (1H, s, OH); *ketone* (45%): 1.27 (3H, t, *J* = 7.2 Hz, OCH₂CH₃), 2.18 (3H, s, CH₃CO), 4.23 (2H, m, OCH₂CH₃), 4.69 (1H, s, PhCH), 7.14–7.38 (5H, m, Ar-H).



Ethyl 3-oxo-2,3-diphenyl-propanoate

To a solution of ethyl 3-oxo-3-phenyl-propionate (1.48 g, 7.7 mmol) in CH_2Cl_2 (25 mL), was added triphenylbismuth carbonate (4.22 g, 8.5 mmol). After being stirred under argon for 24 h at 40°C , the mixture was filtered and concentrated at reduced pressure. The crude was purified by CC (silica; Et_2O / *n*-hexane 1:3) to give a viscous oil. Recrystallization from ethanol yielded the title compound (1.34 g, 65%): mp $88\text{--}89^\circ\text{C}$ (ethanol) (lit.: [21] mp $89\text{--}90^\circ\text{C}$). IR (KBr) ν_{max} (cm^{-1}): 3063, 2985, 1741 (C = O, ester), 1674 (C = O, ketone). ^1H NMR (400 MHz CDCl_3) *keto-enol* equilibrium, *enol* (12%): δ 1.25 (3H, t, $J = 7.2$ Hz, OCH_2CH_3), 4.23 (2H, m, OCH_2CH_3), 7.11 – 7.99 (10 H, m, Ar-H), 13.66 (1H, s, OH), and *ketone* (88%): δ 1.25 (3H, t, $J = 7.2$ Hz, OCH_2CH_3), 4.23 (2H, m, OCH_2CH_3), 5.62 (1H, s, PhCH), 7.11 – 7.99 (10 H, m, Ar-H).


Methyl-4-phenylisoxazolin-5-one

To a solution of ethyl 3-oxo-2-phenyl-butanoate (50 mg, 0.24 mmol) in EtOH (0.5 mL) and H_2O (0.1 mL), was added hydroxylamine hydrochloride (32 mg, 0.46 mmol) and sodium acetate (6.4 mg, 0.078 mmol). The solution was refluxed with continuous stirring under argon for 3 h,

37% HCl (32 μL) was added and the mixture refluxed for further 30 min. The solvent was removed under reduced pressure and the crude diluted with distilled water (2 mL) and extracted with Et_2O (3×5 mL). The organic extract was dried, filtered and concentrated under reduced pressure. Purification by CC (silica; AcOEt) yielded the title compound (32 mg, 66%): mp $138\text{--}140^\circ\text{C}$ (ethyl acetate) (lit.: [22] mp $139\text{--}140^\circ\text{C}$). IR (KBr) ν_{max} (cm^{-1}): 3322 (NH), 1669 (C = O). ^1H NMR (400 MHz CDCl_3) two distinct forms, isoxazol-5(2H)-one (**A**) and isoxazole-5(4H)-one (**B**) (**A**:**B** = 90:10) **A**, δ 2.35 (3H, s, CH_3), 6.24 (1H, sl, NH), 7.14 – 7.56 (5H, m, Ar-H); **B**, δ 2.04 (3H, s, CH_3), 4.40 (1H, s, CH), 7.14 – 7.56 (5H, m, Ar-H).

Diphenylisoxazolin-5-one

To a solution of ethyl 3-oxo-2,3-diphenyl-propanoate (65 mg, 0.27 mmol) in EtOH (0.5 mL) and H_2O (0.1 mL), was added hydroxylamine hydrochloride (32 mg, 0.46 mmol) and sodium acetate (6.4 mg, 0.078 mmol). The solution was refluxed with continuous stirring under argon for 3 h and processed as in the previous reaction to yield the title compound (40 mg, 61%) as a white powder: mp: 159°C (dec.) (benzene) (lit.: [23] mp



159°C). IR (KBr) ν_{\max} (cm⁻¹): 3297 (NH), 1680 (C = O). ¹H NMR (400 MHz CDCl₃) δ 5.86 (1H, sl, NH), 7.01 – 7.79 (10H, m, Ar–H).

General procedure for the synthesis of pyrazolinones

To a stirred ethanolic solution (\approx 0.5 M) of ethyl 3-oxo-2,3-diphenylpropanoate [21] (1 eq.) in ethanol is added the desired hydrazine (1 eq.) and the reaction heated to reflux under argon. After total consumption of both starting materials (TLC control: silica, CH₂Cl₂:MeOH, 9:1), the solvent is evaporated under reduced pressure and the product is purified by hot recrystallization using AcOEt.

Diphenyl-1-methyl-2-pyrazolin-5-one (3a)

From methyl hydrazine, compound **3a** obtained after 18 h as colourless crystals (50%): mp: 214–216°C (AcOEt). ¹H NMR (400 MHz CDCl₃) δ 7.72 – 7.20 (10H, m, Ar–H), 3.70 (3H, s, NCH₃). ¹³C NMR (100.62 MHz CDCl₃) δ 36.4 (NCH₃), 108.4, 124.9, 126.9, 127.2, 129.0, 131.8, 145.3,


165.8 (C = O). IR (KBr; cm⁻¹): 3235 (N–H), 1695 (C = O). EIMS (m/z, %): 250 (M⁺, 100), 178 (58), 77 (26). HRMS: calcd for C₁₆H₁₄N₂O: 250.11076; found: 250.11061.

Triphenyl-2-pyrazolin-5-one (3b)

From phenylhydrazine, compound **3b** obtained after 24 h as colourless crystals (71%): mp 198–199°C (AcOEt). ¹H NMR (400 MHz DMSO-d₆ / CDCl₃, 1:2) δ 10.97 (1H, bs, OH), 7.84 – 7.25 (15H, m, Ar–H). IR (KBr, cm⁻¹): 3236 (N–H), 1697 (C = O). EIMS (m/z, %): 312 (M⁺, 78), 178 (66), 77 (100). HRMS: calcd for C₂₁H₁₆N₂O: 312.12626; found: 312.12661.

Mitsunobu propargylation of pyrazolinones 3

General procedure: To the desired pyrazolinone (**3a** or **3b**) (1.0 eq.) dissolved in dry THF (\approx 0.15 M) under argon, PPh₃ (1.2 eq.) and the required propargyl alcohol (1.0 eq.) are added. The reaction is cooled to 0°C and DIAD (1.2 eq.) in dry THF (\approx 1.5 M) is added dropwise. The



reaction is allowed to reach room temperature and after the reaction is finished (tlc control), the solvent is removed under vacuum. The products are purified by flash chromatography [AcOEt/*n*-hexane, (1:1) \rightarrow AcOEt]. Following the general procedure, compounds (**1a**) and (**2a**) were obtained from **3a**, and **1b** and **2b** from **3b**.

Diphenyl-1-methyl-2-propargylpyrazolin-5-one (**1a**)

(65%), colourless crystals, mp 123–124°C (AcOEt). ^1H NMR (400 MHz CDCl_3) δ 7.47 – 7.34 (6H, m, Ar–H), 7.24 – 7.15 (4H, m, Ar–H), 4.14 (2H, d, $J=2.0$ Hz, $\text{NCH}_2\text{C}\equiv\text{CH}$), 3.49 (3H, s, NCH_3), 2.21 (1H, t, $J=2.0$ Hz, $\text{NCH}_2\text{C}\equiv\text{CH}$). ^{13}C NMR (100.62 MHz CDCl_3) δ 165.5 (C=O), 152.7 [NC(Ph)], 130.4, 130.0, 129.4, 129.0, 129.0, 128.7, 127.9, 126.7, 115.2, 75.4, 74.5, 39.0, 29.2. I.R. (NaCl; cm^{-1}): 3279, 2109, 1651 (C=O). EIMS (m/z, %): 288 (M^+ , 46), 277 (100), 249 ($\text{C}_{16}\text{H}_{13}\text{N}_2\text{O}^+$, 25), 199 (32); 77 (45). HRMS: calcd for $\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}$: 288.126263; found: 288.126523.

3,4-Diphenyl-1-methyl-5-propargyloxy-pyrazole (**2a**)

(35%), colourless oil. ^1H NMR (400 MHz CDCl_3) δ 7.46 – 7.43 (2H, m, Ar–H), 7.34 – 7.22 (8H, m, Ar–H), 4.40 (2H, d, $J=2.4$ Hz, $\text{OCH}_2\text{C}\equiv\text{CH}$), 3.86 (3H, s, NCH_3), 2.49 (1H, t, $J=2.4$ Hz, $\text{OCH}_2\text{C}\equiv\text{CH}$). ^{13}C NMR (100.62 MHz CDCl_3) δ 149.8 [N=C(Ph)], 147.5 [N=C(Ph)C(Ph)=C], 133.7 (Ar), 132.0 (Ar), 129.6 (Ar), 128.5 (Ar), 128.1 (Ar), 127.8 (Ar), 127.4 (Ar), 126.8 (Ar), 105.6 [N=C(Ph)C(Ph)=C], 77.7 ($\text{OCH}_2\text{C}\equiv\text{CH}$), 76.7 ($\text{OCH}_2\text{C}\equiv\text{CH}$), 61.0 ($\text{OCH}_2\text{C}\equiv\text{CH}$), 34.6 (NCH_3). I.R. (NaCl, cm^{-1}): 3289, 2123. EIMS (m/z, %): 288 (M^+ , 40), 249 ($\text{C}_{16}\text{H}_{13}\text{N}_2\text{O}^+$, 100), 221 (18), 178 (5), 115 (25), 91 (20). HRMS: calcd for $\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}$: 288.126263; found: 288.126219.

CH), 61.0 ($\text{OCH}_2\text{C}\equiv\text{CH}$), 34.6 (NCH_3). I.R. (NaCl, cm^{-1}): 3289, 2123. EIMS (m/z, %): 288 (M^+ , 40), 249 ($\text{C}_{16}\text{H}_{13}\text{N}_2\text{O}^+$, 100), 221 (18), 178 (5), 115 (25), 91 (20). HRMS: calcd for $\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}$: 288.126263; found: 288.126219.

2-Propargyl-1,3,4-triphenyl-2-pyrazolin-5-one (**1b**)

(35%), yellowish oil. ^1H NMR (400 MHz CDCl_3) δ 7.65 (2H, d, $J=7.6$ Hz, Ar–H), 7.52 – 7.41 (8H, m, Ar–H), 7.33 – 7.19 (5H, m, Ar–H), 4.03 (2H, d, $J=2.2$ Hz, $\text{NCH}_2\text{C}\equiv\text{CH}$), 2.16 (1H, t, $J=2.2$ Hz, $\text{NCH}_2\text{C}\equiv\text{CH}$). ^{13}C NMR (100.62 MHz CDCl_3) δ 164.6 (C=O), 154.9 [NC(Ph)=C(Ph)], 134.8 (Ar), 130.2 (Ar), 130.1 (Ar), 129.5 (Ar), 129.2 (Ar), 129.0 (Ar), 129.0 (Ar), 128.0 (Ar), 127.0 (Ar), 126.6 (Ar), 123.5 (Ar), 116.6 [NC(Ph)=C(Ph)], 74.6 ($\text{NCH}_2\text{C}\equiv\text{CH}$), 74.1 ($\text{NCH}_2\text{C}\equiv\text{CH}$), 40.6 ($\text{NCH}_2\text{C}\equiv\text{CH}$). IR (film, cm^{-1}): 3298, 2116, 1667 (C=O).

5-Propargyloxy-1,3,4-triphenyl-2-pyrazole (**2b**)

(35%), yellowish oil. ^1H NMR (400 MHz CDCl_3) δ 7.91 (2H, d, $J=7.8$ Hz, Ar–H), 7.58 – 7.30 (13H, m, Ar–H), 4.40 (2H, d, $J=2.3$ Hz, $\text{OCH}_2\text{C}\equiv\text{CH}$), 2.36 (1H, t, $J=2.3$ Hz, $\text{OCH}_2\text{C}\equiv\text{CH}$). ^{13}C NMR (100.62 MHz CDCl_3) δ 149.5 [N=C(Ph)C(Ph)=C], 149.0 [N=C(Ph)C(Ph)=C], 138.5 (Ar), 133.3 (Ar), 131.6 (Ar), 129.9 (Ar), 128.9 (Ar), 128.5 (Ar), 128.1 (Ar), 128.0 (Ar), 127.7 (Ar), 127.1 (Ar), 126.8 (Ar), 122.8 (Ar), 107.9 [N=C(Ph)C(Ph)=C], 77.1 ($\text{OCH}_2\text{C}\equiv\text{CH}$), 76.8 ($\text{OCH}_2\text{C}\equiv\text{CH}$), 61.0 ($\text{OCH}_2\text{C}\equiv\text{CH}$). IR (film, cm^{-1}): 3291, 2125.

General procedure for the thermal rearrangements of pyrazolinones and isomers

In a round bottom flask, the *N*-substituted pyrazolinone or its *O*-substituted isomer dissolved in *o*-dichlorobenzene (ca. 0.04 – 0.05 M), are heated at 180°C until total consumption of the starting material (TLC control). After solvent evaporation the products are purified by flash chromatography [$\text{Et}_2\text{O}/n$ -hexane (1:4)].

Pyrazolinone **4a** from **1a**

Following the general procedure, heating **1a** (30 mg) for 60 min afforded 3,4-diphenyl-1-methyl-4-(prop-1',2'-dienyl) pyrazolin-5-one (**4a**) (10.5 mg, 35%) as a colourless crystals: mp 146–147°C (Et_2O). ^1H NMR (400 MHz CDCl_3) δ 7.56 (2H, d, $J=7.0$ Hz, Ar–H), 7.37 – 7.26 (8H, m, Ar–H), 5.79 (1H, t, $J=6.6$ Hz, $\text{CH}=\text{C}=\text{CH}_2$), 4.90 (1H, dd, $J=11.6, 6.6$ Hz, $\text{CH}=\text{C}=\text{CH}_2$), 4.74 (1H, dd, $J=11.6, 6.6$ Hz, $\text{CH}=\text{C}=\text{CH}_2$), 3.45 (3H, s, NCH_3). ^{13}C NMR (100.62 MHz CDCl_3) δ 208.9, 174.5, 158.8, 136.1, 129.9, 129.2, 128.4, 128.2, 127.0, 89.1, 79.1, 60.1, 31.8. IR (film, cm^{-1}): 3061, 2921, 1956 (C=C=C), 1714 (C=O), 1496. EIMS (m/z, %): 288 (M^+ , 60), 230 (40), 178 (20), 128 (65), 77 (100). HRMS: calcd for $\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}$: 288.126263; found: 288.126455.

Pyrazolinone **4b** from **1b**

Following the general procedure, heating **1b** (14 mg) for 10 min afforded 4-(prop-1',2'-dienyl)-1,3,4-triphenylpyrazolin-5-one (**4b**) (10.1 mg, 72%) as a colourless oil. ¹H NMR (400 MHz CDCl₃) δ 8.07 (2H, d, *J* = 7.8 Hz, Ar-H), 7.70 (2H, d, *J* = 7.8 Hz, Ar-H), 7.47 – 7.23 (11H, m, Ar-H), 5.90 (1H, t, *J* = 6.7 Hz, CH = C = CH₂), 4.94 (1H, dd, *J* = 11.7, 6.7 Hz, CH = C = CH₂), 4.77 (1H, dd, *J* = 11.7, 6.7 Hz, CH = C = CH₂). ¹³C NMR (100.62 MHz CDCl₃) δ 209.0 (CH = C = CH₂), 172.7 (C = O), 159.1 (N = C), 138.2, 136.0, 130.2, 130.1, 129.3, 128.9, 128.4, 127.4, 127.0, 125.3, 119.1, 89.1 (CH = C = CH₂), 79.5 (CH = C = CH₂), 61.6 (C-CH = C = CH₂). IR (film, cm⁻¹): 3063, 2921, 1954 (C = C = C), 1721 (C = O), 1596, 1494. EIMS (m/z, %): 350 (M⁺, 25), 230 (12), 178 (10), 128 (21), 91 (32), 77 (100). HRMS: calcd for C₂₄H₁₈N₂O: 350.141913; found: 350.142194.

Pyrazolinone **4a** from isomer **2a**

Following the general procedure, heating **2a** (20 mg) for 10 min afforded 3,4-diphenyl-1-methyl-4-(prop-1',2'-dienyl)pyrazolin-5-one (**4a**) (18 mg, 90%) as a white solid with data identical with 4.4.1.

Pyrazolinone **4b** from isomer **2b**

Following the general procedure, heating **2b** (24 mg) for 10 min afforded 4-(prop-1',2'-dienyl)-1,3,4-triphenylpyrazolin-5-one (**4b**) (24 mg, 99%) as a white solid with data identical with 4.4.2.

Pyrazolinone **6a** from **5a**

Following the general procedure, heating **5a** (10 mg) for 30 min afforded the pyrazolinone **6a** (3 mg, 30%) as a glassy solid. ¹H NMR (400 MHz CDCl₃) δ 7.52 (2H, d, *J* = 7.3 Hz, Ar-H), 7.38 – 7.22 (8H, m, Ar-H), 3.47 (3H, s, NCH₃), 3.43 (1H, dd, *J* = 16.0 Hz, 2.5 Hz, CH₂C ≡ CH), 3.05 (1H, dd, *J* = 16.0, 2.5 Hz, CH₂C ≡ CH), 1.91 (1H, t, *J* = 2.5 Hz, CH₂C ≡ CH). IR (film, cm⁻¹): 3291 (C ≡ C-H), 2923, 1956 (C ≡ C), 1713 (C = O).

Pyrazolinone **6a** from isomer **7a**

Following the general procedure, heating **7a** (10 mg) for 10 min afforded **6a** (8 mg, 80%) with data identical with the previous reaction.

Reactions of pyrazolinones with base

In a round bottom flask, the propargylated pyrazolinone **1a** or its isomer **2a** is dissolved in dry THF (ca. 0.07 M) (1 eq.) under argon and 18-crown-6 ether (1 eq.) is added. After total dissolution of the reactants, EtOK (0.1 eq.) is added under anhydrous conditions. The reaction is left to react at room temperature. After consumption of the starting material (TLC control) the reaction is stopped by addition of a saturated solution of NH₄Cl

and extraction with Et₂O (2x). The product is purified by flash chromatography [AcOEt / *n*-hexane (1:6)].

Pyrazolinone **6a** from isomer **7a**

Following the general procedure, 3,4-diphenyl-1-methyl-2-(prop-1',2'-dienyl)pyrazolin-5-one (**5a**) was obtained from **1a** after 16 h as a colourless oil (65%). ¹H NMR (400 MHz CDCl₃) δ 7.69 – 7.64 (4H, m, Ar-H), 7.56 – 7.52 (2H, m, Ar-H), 7.47 – 7.43 (4H, m, Ar-H), 6.30 (1H, t, *J* = 6.2 Hz, N-CH = C = CH₂), 5.32 (2H, d, *J* = 6.2 Hz, NCH = C = CH₂), 3.49 (3H, s, NCH₃). IR (film, cm⁻¹): 3055, 2925, 1962 (C = C = C), 1659 (C = O), 1483.

Isomer **7a** from **2a**

Following the general procedure, 1-methyl-3,4-diphenyl-5-(prop-1',2'-dienyloxy)pyrazole (**7a**) was obtained from **2a** after 16 h as a colourless oil (74%). ¹H NMR (400 MHz CDCl₃) δ 7.47 – 7.43 (2H, m, Ar-H), 7.34 – 7.24 (8H, m, Ar-H), 6.79 (1H, t, *J* = 5.9 Hz, OCH = C = CH₂), 5.36 (2H, d, *J* = 5.9 Hz, OCH = C = CH₂), 3.81 (3H, s, NCH₃). ¹³C NMR (100.62 MHz CDCl₃) δ 200.0 (OCH = C = CH₂), 147.7, 147.5, 133.5 (Ar), 131.6, 129.6, 129.2, 128.3, 128.2, 127.9, 127.6, 126.7, 121.7 (OCH = C = CH₂), 93.0 (OCH = C = CH₂), 34.7 (NCH₃). IR (film, cm⁻¹): 3059, 2940, 1972 (C = C = C), 1605, 1563.

Synthesis of isoxazolinones

Diphenyl-2-(prop-2'-yn-1'-yl)isoxazolin-5-one (8a)

To a solution of 3,4-diphenylisoxazolin-5-one (Section 4.2.4) (100 mg, 0.422 mmol), triphenylphosphine (121 mg, 0.46 mmol) and propargylic alcohol (21.5 mg, 0.384 mmol) in dry THF (1.5 mL) were added, dropwise, DIAD (93 mg, 0.460 mmol). After the addition was completed, the solvent was removed under reduced pressure and the crude purified by CC (silica; Et₂O / *n*-hexane 1:2) to yield the title compound **8a** (22 mg, 21 %): mp 81–82°C (Et₂O / *n*-hexane). IR (KBr, cm⁻¹): 3291 (HC≡C), 2127 (C≡C), 1746 (C = O). ¹H NMR (400 MHz CDCl₃) δ 2.64 (1H, s, HC≡C), 5.06 (2H, d, *J* = 2.1 Hz, NCH₂), 7.26 – 7.56 (10H, m, Ar-H). EIMS (m/z, %): 275 (M⁺, 23), 178 (34), 105 (100), 89 (60), 77 (50). HRMS calcd for C₁₈H₁₃NO₂: 275.09463; found: 275.09405.

Diphenyl-2-(2'-methylbut-3'-yn-2'-yl)isoxazolin-5-one (8b)

Following Nicholas protocol [24], to a stirred solution of 2-methylbut-3-yn-2-ol (25.2 mg, 0.3 mmol) in petroleum ether (2 mL), under nitrogen at RT, was added Co₂(CO)₈ (102.6 mg, 0.3 mmol) and MS 4 Å, followed by boron trifluoride diethyl etherate (42.5 mg, 0.3 mmol). After 10 min 3,4-diphenylisoxazolin-5-one (Section 4.2.4) (23.7 mg, 0.1 mmol) was added and the reaction monitored by TLC (silica; CH₂Cl₂ / AcOEt 4:1) until consumption of the starting isoxazolone. After 48 h water (5 mL) was added to the reaction mixture which was extracted with

Et₂O (2x5 mL) to yield the cobalt complex as a red oil, which was purified by PTLC (silica; *n*-hexane / AcOEt 4:1). To a solution of this red complex in acetone (2 mL) was added Et₃N (0.1 mmol) and (NH₄)₂Ce(NO₃)₆ (55 mg, 0.1 mmol) until formation of the required isoxazolinone. Water was added (10 mL), followed by extraction of the mixture with Et₂O (3x5 mL) and purification by PTLC (silica; Et₂O / *n*-hexane 1:1) afforded the *N*-substituted isoxazolinone **8b** (17.6 mg, 58%): mp 113–115°C (Et₂O / *n*-hexane). IR (KBr, cm⁻¹): 3291 (HC≡C), 2113 (C≡C), 1746 (s, C=O). ¹H NMR (400 MHz CDCl₃) δ 1.48 (6H, s, CH₃), 2.31 (1H, s, HC≡C), 7.19 – 7.50 (10H, m, Ar–H). ¹³C-NMR (100.62 MHz CDCl₃) δ 28.5 [NC(CH₃)₂], 61.3 [NC(CH₃)₂], 73.7 (HC≡C), 82.4 (HC≡C), 127.4, 128.2, 128.3, 128.7, 129.5, 130.6, 170.2. EIMS (m/z, %): 303 (M⁺, 17), 237 (C₁₅H₁₁NO₂⁺, 100), 178 (35), 67 (40). HRMS: calcd for C₂₀H₁₇NO₂: 303.12593; found: 303.12641.

Allyl-3-methyl-4-phenylisoxazolin-5-one (8c)

To 3-methyl-4-phenylisoxazolin-5-one (Section 4.2.3) (0.3 g, 1.71 mmol) was added a solution of Na (39 mg) in EtOH (1.7 mL). To this solution was added allyl bromide (0.207 mg, 1.71 mmol). The reaction mixture was magnetically stirred, under argon, while being heated under reflux (1.8 h). On completion of the reaction (TLC control: silica; 1) Et₂O / *n*-hexane 1:1, 2) AcOEt, the solvent was removed under reduced pressure. Purification by CC (silica; Et₂O / *n*-hexane 1:1) afforded the title compound **8c** (171.6 mg, 66%) as a white solid: mp 50–51°C (Et₂O / *n*-hexane). IR (KBr, cm⁻¹): To 3-methyl-4-phenylisoxazolin-5-one (Section 4.2.3) (0.3 g, 1.71 mmol) was added a solution of Na (39 mg) in EtOH (1.7 mL). To this solution was added allyl bromide (0.207 mg, 1.71 mmol). The reaction mixture was magnetically stirred, under argon, while being heated under reflux (1.8 h). On completion of the reaction (TLC control: silica; 1) Et₂O / *n*-hexane 1:1, 2) AcOEt, the solvent was removed under reduced pressure. Purification by CC (silica; Et₂O / *n*-hexane 1:1) afforded the title compound **8c** (171.6 mg, 66%) as a white solid: mp 50–51°C (Et₂O / *n*-hexane). IR (KBr, cm⁻¹): 1711 (C=O), 1604 (C=C). ¹H NMR (400 MHz CDCl₃) δ 2.29 (3H, s, CH₃), 4.27 (2H, d, J = 6 Hz, NCH₂), 5.30 (2H, m, CH₂ = CH), 5.80 (1H, m, CH₂ = CH), 7.27 (1H, t, J = 7.4 Hz, *p*-Ar–H), 7.38 (2H, t, J = 7.5 Hz, *m*-Ar–H), 7.46 (2H, d, J = 7.6 Hz, *o*-Ar–H). ¹³C-NMR (100.62 MHz CDCl₃) δ 11.8 (CH₃), 53.1 (N–CH₂), 103.8 [N–C(Me) = C(Ph)], 120.5 (CH₂ = CH), 127.2 (Ar), 128.2 (Ar), 128.5 (Ar), 129.4 (Ar), 129.6 (CH₂ = CH), 159.3 [N–C(Me) = C(Ph)], 169.5 (C=O). EIMS (m/z, %): 215 (M⁺, 100), 130 (21), 116 (38), 115 (46), 89 (13), 77 (13). HRMS: calcd for C₁₃H₁₃NO₂: 215.09463; found: 215.09397.

Allyl-3,4-diphenylisoxazolin-5-one (8d)

3,4-Diphenylisoxazolin-5-one (Section 4.2.4) (0.406 g, 1.71 mmol), using the previous protocol, afforded the title compound (**8d**) (256 mg, 85%) as a white solid: mp 105–106°C (Et₂O / *n*-hexane). IR (KBr, cm⁻¹): 1720 (C=O), 1615 (C=C). ¹H NMR (400 MHz CDCl₃) δ 4.06 (2H, d, J = 6.0 Hz, NCH₂), 5.16 (1H, d, J = 17.2 Hz, CH₂ = CH), 5.25 (1H, d, J = 10.8 Hz, CH₂ = CH), 5.78 (1H, m, CH₂ = CH), 7.18 – 7.48 (10 H, m, Ar–H). ¹³C NMR (100.62 MHz CDCl₃) δ 54.9 (N–CH₂), 105.2 [N–C(Ph) = C(Ph)], 121.0 (CH₂ = CH), 127.2 (Ar), 127.7 (Ar), 128.2 (Ar), 128.3(Ar), 128.7(Ar), 129.0(Ar), 129.2(Ar), 129.3(Ar), 131.0 (CH₂ = CH), 162.8 [N–C(Ph)], 169.9 (C=O). EIMS (m/z, %): 277 (M⁺, 100), 236 (12), 192 (27), 178 (76), 133 (13), 117 (51), 89 (46), 77 (22). HRMS: calcd for C₁₈H₁₅NO₂: 277.11028; found: 277.11037.

Synthesis of isoxazolidinone 8e

Diethyl 2-[(allyl-(tert-butyl)dimethylsilyloxy)amino]methylene]malonate (10) To a stirred solution of *N*-tert-butyl)dimethylsilyloxyprop-2-en-1-amine (0.5 g, 2.67 mmol) in CCl₄ / CHCl₃ (1:3) (20 mL) under argon was added diethyl 2-(ethoxymethylene)malonate [7] (0.58 g, 2.67 mmol, 1 eq.). On completion of the reaction (TLC control: silica, Et₂O / *n*-hexane 1:1) (30 h), the solvent was removed under reduced pressure by CC (silica; Et₂O / *n*-hexane 1:1) to afford the title compound **10** (50%) as an oil (50%): IR (film, cm⁻¹) 1732 (C=O), 1707 (C=O), 1621 (C=C), 1262 (Si–O–N). ¹H NMR (400 MHz CDCl₃) δ 0.19 [6H, s, Si(CH₃)₂], 0.93 [9H, s, C(CH₃)₃], 1.23 (6H, m, OCH₂CH₃), 4.00 (2H, d, J = 6.0 Hz, NCH₂), 4.12 (4H, m, OCH₂CH₃), 5.26 (1H, d, J = 10.4 Hz, CH₂ = CH), 5.35 (1H, d, J = 17.3 Hz, CH₂ = CH), 5.90 (1H, m, CH₂ = CH), 7.88 (1H, s, N–CH = C). ¹³C NMR (100.62 MHz CDCl₃) δ -5.3 [Si(CH₃)₂], 14.1 (OCH₂CH₃), 17.8 [C(CH₃)₃], 25.8 [C(CH₃)₃], 59.9 (CH₂N), 60.3 (OCH₂CH₃), 60.6 (OCH₂CH₃), 61.4 (NCH = C), 119.6 (CH₂ = CH), 131.1 (CH₂ = CH), 149.5 (N–CH), 166.2 (C=O). EIMS (m/z, %): 357 (M⁺, 66), 312 ([M–C₂H₅O]⁺, 86), 300 ([M–C₄H₉]⁺, 100), 226 ([M–C₆H₁₅OSi]⁺, 97), 198 (20), 57 (C₄H₉⁺, 49). HRMS: calcd for C₁₇H₃₁NO₅Si: 357.19715; found: 357.19796.

Diethyl 2-[(allyl-(tert-butyl)dimethylsilyloxy)amino]methylene]malonate (10) To a magnetically stirred solution of 2-[(allyl-(tert-butyl)dimethylsilyloxy)amino]methylene]malonate [5] (**10**) (50 mg, 0.140 mmol) in CH₃CN [6 mL, 0.1% H₂O (m/v)], at RT under nitrogen, was added SbCl₅ (359 μL, from 0.039 M solution in CH₃CN, 0.1 eq.). On completion of the reaction (10 m), (TLC control: silica; Et₂O / *n*-hexane 1:1), the solvent was removed under reduced pressure. Purification by CC (silica; Et₂O / *n*-hexane 1:1) afforded diethyl 2-[(allyl

(hydroxyl)amino) methylene]malonate (**11**) (23 mg, 68%), and ethyl 2-allyl-5-oxo-2,5-dihydroisoxazole-4-carboxylate (**8e**) (3.3 mg, 12%). Compound **11** was unstable and lactonised spontaneously on standing to the 2-allyl-isoxazolinone **8e**.

Ethyl 2-allyl-5-oxo-2,5-dihydroisoxazole-4-carboxylate (8e) Colourless crystals, mp 45–46°C (*n*-hexane). IR (film, cm⁻¹): 1784 (C=O, ester), 1698 (C=O), 1578 (C=C). ¹H NMR (400 MHz CDCl₃) δ 1.30 (3H, t, *J* = 7.1 Hz, OCH₂CH₃), 4.26 (2H, q, *J* = 7.1 Hz, OCH₂CH₃), 4.47 (2H, d, *J* = 6.3 Hz, NCH₂), 5.46 (2H, m, CH₂ = CH), 5.89 (1H, m, CH₂ = CH), 8.34 (H, s, N–CH). Elemental analysis: calcd for C₉H₁₁NO₄ (%): C: 54.80, H: 5.63, N: 7.11. Found (%): C: 54.53, H: 5.66, N: 7.01.

Diethyl 2-[(*N*-allyl(hydroxyl)amino)methylene] malonate (11) Oil, IR (film, cm⁻¹): 3600 – 1800 (l, OH), 1685 (C=O), 1629 (C=C). ¹H NMR (400 MHz CD₃CN) δ 1.26 (3H, t, *J* = 7.1 Hz, OCH₂CH₃), 1.33 (3H, t, *J* = 7.1 Hz, OCH₂CH₃), 4.16 (2H, q, *J* = 7.1 Hz, OCH₂CH₃), 4.25 (4H, m, OCH₂CH₃ + NCH₂), 5.39 (2H, m, CH₂ = CH), 5.96 (1H, m, CH₂ = CH), 7.86 (1H, s, N–CH = C), 13.11 (1H, s, OH, exchange D₂O). ¹³C NMR (100.62 MHz CD₃CN) δ 14.1 (OCH₂CH₃), 30.2 (CCO₂Et), 60.0 (OCH₂CH₃), 61.5 (OCH₂CH₃), 61.6 (NCH₂), 120.8 (CH = CH₂), 129.9 (CH = CH₂), 147.3 (NCH = C), 166.2 (C=O). EIMS (m/z, %) 243 (M⁺, 2), 197 (C₉H₁₁NO₄⁺, 100). HRMS: calcd for C₁₁H₁₇NO₅: 243.11067; found: 243.10985.

General procedure for the thermal rearrangements of isoxazolinones

In a round bottom flask, the isoxazolinones (**8a-e**) dissolved in *o*-dichlorobenzene (ca. 0.04 – 0.05 M) are heated until total consumption of the starting material (TLC control). After solvent evaporation the products are purified by flash chromatography.

Rearrangement of the 3,4-diphenyl-2-(prop-2'-yn-1'-yl)isoxazolin-5-one (8a)

Following the general procedure, 3,4-diphenyl-4-(prop-1',2'-dien-1'-yl)isoxazolin-5-one (**9a**) was obtained by heating **8a** (10 mg) at 60°C for 30 m, followed by CC (silica; Et₂O / *n*-hexane 1:1), as an oil (75%): IR (film, cm⁻¹): 1965 (C=C=C), 1798 (C=O). ¹H NMR (400 MHz CDCl₃) δ 4.88 (1H, dd, *J* = 6.6, 12.1 Hz, CH=C=CH₂), 5.04 (1H, dd, *J* = 6.6, 12.1 Hz, CH=C=CH₂), 5.80 (1H, t, *J* = 6.6 Hz, HC=C=CH₂), 7.30 – 7.58 (10H, m, Ar–H). ¹³C NMR (100.62 MHz CDCl₃) δ 57.8 [N=C(Ph)C], 80.6 (CH=C=CH₂), 88.0 (CH=C=CH₂), 126.9 (Ar), 127.1 (Ar), 127.7 (Ar), 128.8 (Ar), 129.2 (Ar), 129.6 (Ar), 131.6 (Ar), 134.3 (Ar), 166.6 (N=C), 175.1 (C=O), 203.0 [CH=C=C(CH₃)₂]. EIMS (m/z, %): 275 (M⁺, 19),

231 ([M-CO₂]⁺, 100), 172 (89), 128 (99), 102 (89), 77 (82). HRMS: calcd for C₁₈H₁₃NO₂: 275.09463; found: 275.09556.

Rearrangement of 3,4-diphenyl-2-(2'-methylbut-3'-yn-2'-yl)isoxazolin-5-one (8b)

Following the general procedure, 3,4-diphenyl-4-(3'-methylbut-1',2'-dien-1'-yl)isoxazolin-5-one (**9b**) was obtained by heating **8b** at 60°C for 10 m, followed by CC (silica; Et₂O / *n*-hexane 1:1), as a colourless solid (85%): mp 77–80 (Et₂O / *n*-hexane). IR (KBr, cm⁻¹): 1969 (C=C=C), 1790 (C=O). ¹H NMR (400 MHz CDCl₃) δ 1.37 (3H, s, CH₃), 1.62 (3H, s, CH₃), 5.65 (1H, t, *J* = 2.6 Hz, HC=C=C), 7.28 – 7.54 (10H, m, Ar–H). ¹³C NMR (100.62 MHz CDCl₃) δ 19.3 (CH₃), 19.7 (CH₃), 58.5 [N=C(Ph)C], 86.6 [CH=C=C(CH₃)₂], 102.2 (CH=C=C(CH₃)₂), 127.0 (Ar), 127.7 (Ar), 128.1 (Ar), 128.5 (Ar), 128.9 (Ar), 129.4 (Ar), 129.7 (Ar), 131.2 (Ar), 132.2 (Ar), 134.7 (Ar), 167.2 (N=C), 177.5 (C=O), 203.5 (CH=C=C(CH₃)₂). EIMS (m/z, %) 303 (M⁺, 1), 288 ([M-CH₃]⁺, 29), 259 ([M-CO₂]⁺, 53), 244 (C₁₈H₁₄N⁺, 50), 200 (C₁₃H₁₂O₂⁺, 100), 141 (C₁₁H₉⁺, 71), 89 (C₇H₅⁺, 20), 77 (C₆H₅⁺, 76).

Rearrangement of 2-allyl-3-methyl-4-phenylisoxazolin-5-one (8c)

Following the general procedure, 4-allyl-3-methyl-4-phenylisoxazolin-5-one (**9c**) was obtained by heating **8c** at 180°C for 7 h, followed by CC (silica; Et₂O / *n*-hexane 1:1), as a viscous oil (95%): IR (film, cm⁻¹): 1791 (C=O), 1643 (C=N). ¹H NMR (400 MHz CDCl₃) δ 1.95 (3H, s, CH₃), 2.85 (1H, dd, *J* = 7.8, 13.7 Hz, C–CH₂), 3.10 (1H, dd, *J* = 6.7, 13.7 Hz, C–CH₂), 5.25 (1H, d, *J* = 10.1 Hz, CH₂ = CH), 5.30 (1H, d, *J* = 16.9 Hz, CH₂ = CH), 5.60 (1H, m, CH₂ = CH), 7.20 – 7.44 (5H, m, Ar–H). ¹³C NMR (100.62 MHz CDCl₃) δ 12.4 (CH₃), 36.4 (C–CH₂), 59.3 (C–CH₂), 121.4 (CH₂ = CH), 126.2 (Ar), 127.3, 127.8, 128.9, 129.5, 129.7, 133.3 (CH₂ = CH), 168.3 (C=N), 178.7 (C=O). EIMS (m/z, %): 215 (M⁺, 100), 116 (15), 115 (40), 77 (30). HRMS: calcd for C₁₃H₁₃NO₂: 215.09463; found: 215.09414.

Rearrangement of 2-allyl-3,4-diphenylisoxazolin-5-one (8d)

Following the general procedure, 4-allyl-3-methyl-3,4-phenylisoxazolin-5-one (**9d**) was obtained by heating **8d** at 180°C for 5 h, followed by CC (silica; Et₂O / *n*-hexane 1:1), as a pale yellow solid (97%): mp 71–72°C. IR (KBr, cm⁻¹): 1800 (f, C=O), 1644 (C=N). ¹H NMR (400 MHz CDCl₃) δ 3.03 (1H, dd, *J* = 7.2, 13.2 Hz, C–CH₂), 3.32 (1H, dd, *J* = 7.6, 13.2 Hz, C–CH₂), 5.25 (1H, d, *J* = 16.9 Hz, CH₂ = CH), 5.14 (1H, d, *J* = 10.1 Hz, CH₂ = CH), 5.54 (1H, m, CH₂ = CH), 7.33 – 7.52 (10H, m, Ar–H). ¹³C NMR (100.62 MHz CDCl₃) δ 37.5 (C–CH₂), 58.8 (C–CH₂), 121.8 (CH₂ = CH), 126.3 (Ar), 127.2 (Ar), 127.4

(Ar), 128.9 (Ar), 129.0 (Ar), 129.4 (Ar), 129.7 (Ar), 131.7 (CH₂ = CH), 134.4 (Ar), 167.1 (N = C), 169.9 (C = O). EIMS (m/z, %): 277 (M⁺, 100), 236 ([M-C₃H₅]⁺, 12), 232 (21), 178 (49), 117 (51), 103 (35), 77 (30). HRMS: calcd for C₁₈H₁₅NO₂: 277.11028; found: 277.10956.

Rearrangement of the ethyl 2-allyl-5-oxo-2,5-dihydroisoxazole-4-carboxylate (**8e**)

Following the general procedure, ethyl 2-cyanopent-4-enoate (**12**) was obtained by heating **8e** at 180°C for 5 h, followed by CC (silica; Et₂O / *n*-hexane 1:1), as a colourless oil [**13**] (80%): IR (film, cm⁻¹): 2266 (C≡N), 1750 (C = O). ¹H NMR (400 MHz CDCl₃) δ 1.32 (3H, t, *J* = 7.1 Hz, OCH₂CH₃), 2.69 (2H, m, CHCH₂CH), 3.56 (1H, t, *J* = 6.8 Hz, NC-CH), 4.27 (2H, q, *J* = 7.1 Hz, OCH₂CH₃), 5.25 (2H, m, CH₂ = CH), 5.83 (1H, m, CH₂ = CH).

Reaction of isoxazolinones with base

Reaction of 2-allyl-3,4-diphenylisoxazolin-5-one (**8d**)

To a stirred solution of compound **8d** (80 mg, 0.289 mmol) in dry 1,4-dioxane (2 mL) at RT under argon, potassium ethoxide (1.5 eq., 36.5 mg, 0.434 mmol) and 18-crown-6 ether (114.7 mg, 0.434 mmol) were added. After 10 min the reaction was found complete (TLC control: silica; Et₂O / *n*-hexane 3:1), the mixture was neutralized with aq. 0.5 N AcOH and the solvent removed under reduced pressure. The crude was diluted with Et₂O (5 mL) and washed with distilled water (2 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. Purification by CC (silica; Et₂O / *n*-hexane 3:1) afforded 2-(2'-ethoxyethyl)-4,5-diphenyl-2,3-dihydro-1,3-oxazin-6-one (**14**) (23.3 mg, 25%) as a yellow oil: IR (film, cm⁻¹): 3257 (NH), 1694 (C = O), 1600, 1585, 1553. ¹H NMR (400 MHz CDCl₃) δ 1.05 (3H, t, *J* = 7.0 Hz, OCH₂CH₃), 2.22 (2H, m, CHCH₂), 3.44 (2H, m, OCH₂CH₃), 3.62 (1H, m, OCH₂CH₂), 3.77 (1H, m, OCH₂CH₂), 5.47 (1H, q, *J* = 4.9 Hz, CHCH₂), 6.46 (1H, d, *J* = 4.1 Hz, NH - exchange D₂O), 7.02 - 7.24 (10H, m, Ar-H). ¹³C NMR (100.62 MHz CDCl₃) δ 15.0 (OCH₂CH₃), 32.0 (OCH₂CH₂), 65.7 (OCH₂CH₃), 66.6 (OCH₂CH₂), 81.6 (N-CH-O), 103.9 (N-C = C-CO), 126.1 (Ar), 127.6 (Ar), 128.2 (Ar), 129.8 (Ar), 130.2 (Ar), 131.4 (Ar), 133.9 (Ar), 134.9 (Ar), 155.5 (N-C = C-CO), 166.3 (C = O). EIMS (m/z, %) 323 (M⁺, 100), 250 (C₁₆H₁₂NO₂⁺, 90), 178 (C₁₄H₁₀⁺, 99), 77 (C₆H₅⁺, 43). HRMS: calcd for C₂₀H₂₁NO₃: 323.15214; found: 323.15254; and deoxybenzoin (**15**, R = H) (25.5 mg, 45%) as a colourless solid: mp 55-56°C (lit.: [25] mp 55-56°C). IR (KBr, cm⁻¹): 1686 (C = O). ¹H NMR (400 MHz CDCl₃) δ 4.29 (2H, s, CH₂), 7.24 - 8.04 (10 H, m, Ar-H). After the reaction in a parallel run was completed, glacial CH₃COOD (3.0 eq.) was added to the reaction followed by H₂O (2 mL). The reaction mixture was diluted with Et₂O (5 mL) and washed with an aqueous solution of

1M NaHCO₃. The aqueous layer was extracted with Et₂O (3 × 5 mL), the combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated. Purification by CC (silica; Et₂O / *n*-hexane 1:1) afforded mono-deuterated deoxybenzoin (**15**, R = D) (37.5 mg, 66%): ¹H NMR (400 MHz CDCl₃) δ 4.29 (1H, s, CHD), 7.23 - 8.06 (10 H, m, Ar-H).

Reaction of ethyl 2-allyl-5-oxo-2,5-dihydroisoxazole-4-carboxylate (**8e**)

To a stirred solution of compound **8e** (50 mg, 0.254 mmol) in dry 1,4-dioxane (1 mL) at RT under argon, was added potassium ethoxide (32 mg, 0.38 mmol, 1.5 eq.) and 18-crown-6 ether (100 mg, 0.38 mmol). On completion of the reaction (5 h, TLC control: silica; Et₂O), the solvent was removed under reduced pressure and the crude purified by cc (silica; Et₂O). *N*-Allylmalonic acid ethyl ester (**13**) was obtained as a white solid (34.7 mg, 80%): mp 40-41°C (Et₂O). IR (KBr) ν_{max} (cm⁻¹): 3299 (NH), 1740 (C = O ester), 1659 (C = O amide). ¹H NMR (400 MHz CDCl₃) δ 1.22 (3H, t, *J* = 7.1, OCH₂CH₃), 3.26 (2H, s, COCH₂COOEt), 3.84 (2H, t, *J* = 5.6 Hz, NH-CH₂), 4.13 (2H, q, *J* = 7.1 Hz, OCH₂CH₃), 5.07 (1H, dd, *J* = 1.1, 10.3 Hz, CH₂ = CH), 5.14 (1H, dd, *J* = 1.3, 17.1 Hz, CH₂ = CH), 5.80 (1H, m, CH₂ = CH), 7.29 (1H, bs, NH exchange D₂O). ¹³C NMR (100.62 MHz CDCl₃) δ 14.0 (COOCH₂CH₃), 41.3 (COCH₂COOEt), 41.8 (NHCH₂), 61.5 (COOCH₂CH₃), 116.2 (CH₂ = CH), 133.7 (CH₂ = CH), 165.0 (NHC = O), 169.3 (COOEt). EIMS (m/z, %): 171 (M⁺, 10), 56 (C₃H₆N⁺, 100). HRMS: calcd for C₈H₁₃NO₃: 171.08954; found: 171.08894.

Reactions of 2-(2'-methylbut-3'-yn-2'-yl)-3,4-diphenylisoxazolin-5-one (**8b**)

With 1.5 eq. of EtOK To a stirred solution of compound (**8b**) (15 mg, 0.055 mmol) in dry 1,4-dioxane (0.25 mL), under argon, was added potassium ethoxide (1.5 eq., 7.0 mg, 0.083 mmol) and 18-crown-6 ether (21.8 mg, 0.083 mmol). On completion of the reaction (10 min) (TLC control: silica; Et₂O / *n*-hexane 3:1), the mixture was neutralized with aq. AcOH 0.5 N and the solvent removed under reduced pressure. The crude was diluted with Et₂O (5 mL) and washed with distilled H₂O (2 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. Purification by CC (silica; Et₂O / *n*-hexane 3:1) afforded 4-(3'-methylbut-1',2'-dienyl-1'-yl)-3,4-diphenylisoxazolin-5-one (**9b**) (4.5 mg, 30%). After 30 min of reaction, no rearrangement product could be still detected by TLC.

With 0.1 eq. of EtOK Using the previous conditions with potassium ethoxide (0.1 eq.) and 18-crown-6 ether (0.1 eq.), the reaction after 5 days yielded **9b** (55%).

With LDA To a stirred solution of **8b** (1 eq.) in dry 1,4-dioxane, under argon, were added LDA (1.5 eq., from a 1.47 M solution) and 12-crown-4 ether (1.5 eq.). The reaction mixture was stirred for 48 h. TLC control (silica; Et₂O / *n*-hexane 3:1) showed no reaction and the starting material was recovered yield (5.4 mg, 90%).

With tert-BuLi To a stirred solution of **8b** (1 eq.) in dry 1,4-dioxane, under argon, were added *tert*-BuLi (2 eq., from an hexane solution 0.8 M, 0.066 mmol) and 12-crown-4 ether (2 eq.). The reaction mixture was stirred for 70 h. TLC control (silica; Et₂O / *n*-hexane 3:1) showed no reaction and the starting material was recovered (9.5 mg, 95%).

Endnote

^a Web Table (which contains energy profiles, molecular coordinates of intermediates and transition states as well as normal mode animations) is available via the HTML version of the article.

Additional file

Additional file 1: Table S1. Calculated relative energies for intermediates and transition states relating to Scheme 6.

Competing interests

The authors declare that they have no competing interest.

Authors' contributions

AML, HSR and SP contributed equally to this work. LFVP, MJSG and PMCG carried out the experimental work. All authors read and approved the final manuscript.

Acknowledgements

We thank Fundação para a Ciência e a Tecnologia (FC&T, Lisbon, Portugal) for financial support from grant PEst-C/EQB/LA 0006/2011 and Project POCTI/QUI/36456. Three of us (M.J.S.G., L.F.V.P., P.M.C.G.) are grateful for the award of research fellowships from FC&T.

Author details

¹Chemistry Department, REQUIMTE/CQFB, FCT, Universidade Nova de Lisboa, 2829-516, Caparica, Portugal. ²Departamento das Ciências Naturais e Exatas, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisboa, Portugal. ³Chemistry Department, Imperial College London, South Kensington Campus, London, UK.

Received: 20 March 2013 Accepted: 6 May 2013

Published: 28 May 2013

References

1. Nubbemeyer U: **Recent advances in charge-accelerated Aza-Claisen rearrangements.** *Top Curr Chem* 2005, **244**:149–213. and references cited therein.
2. Weston MH, Nakajima K, Back TG: **Tandem conjugate additions and 3-aza-Cope rearrangements of tertiary allyl amines and cyclic alpha-vinylamines with acetylenic sulfones. Applications to simple and iterative ring expansions leading to medium and large-ring nitrogen heterocycles.** *J Org Chem* 2008, **73**:4630–4637. and references cited therein.
3. Nubbemeyer U: **Aza-Claisen Rearrangement.** In *The Claisen Rearrangement: Methods and Applications.* Edited by Hiersemann M, Nubbemeyer U. Weinheim: Wiley-VCH; 2007:461.

4. Glória PMC, Prabhakar S, Lobo AM: **Studies in N-amino-3-aza Cope rearrangements.** *Tetrahedron Lett* 2008, **49**:7355–7357.
5. Gomes MJS, Sharma L, Prabhakar S, Lobo AM, Glória PMC: **Studies in 3-oxy-assisted 3-aza Cope rearrangements.** *Chem Commun* 2002:746–747.
6. Hastings CJ, Fiedler D, Bergman RG, Raymond KN: **Aza Cope Rearrangement of Propargyl Enammonium Cations Catalyzed By a Self-Assembled 'Nanozyme'.** *J Am Chem Soc* 2008, **130**:10977–10983.
7. Pinto LFV, Glória PMC, Gomes MJS, Rzepa HS, Prabhakar S, Lobo AM: **A dramatic effect of double bond configuration in N-oxy-3-aza Cope rearrangements—a simple synthesis of functionalised allenes.** *Tetrahedron Lett* 2009, **50**:3446–3449.
8. Gilbert JC, Cousins KR: **Theoretical and experimental studies of the 3-aza-Claisen rearrangement.** *Tetrahedron* 1994, **50**:10671–10784.
9. Mitsunobu O, Mulder JA, Xiong H, Zificsak CA, Douglas CJ, Hsung RP: **Efficient preparations of novel ynamides and allenamides.** *Tetrahedron* 2001, **57**:459–466.
10. Makisumi Y: **A facile amino-Claisen rearrangement.** *Tetrahedron Lett* 1966, **7**:6413–6417.
11. Makisumi Y, Sasatani T: **Sigmatropic tautomerism between n-allyl-3-isoxazolin-5-ones and 4-allyl-2-isoxazolin-5-ones.** *Tetrahedron Lett* 1969, **10**:543–546.
12. Glória PMC, Prabhakar S, Lobo AM, Gomes MJS: **SbCl₅-wet acetonitrile: a new system for chemoselective O-desilylation.** *Tetrahedron Lett* 2003, **44**:8819–8821.
13. Roustan JLA, Houlihan F: **Electrophilie du ligande η³-allylique de complexes η³-allyl-dicarbonyl-nitrosyl-fer.** *Can J Chem* 1979, **57**:2790–2791.
14. Woodman DJ, Stonebroker PM: **Ketenimine carboxylate isomer protonation.** *Heterocycles* 1977, **7**:247–250. and references cited therein.
15. Khalafy J, Marjani AP, Ebrahimbo ARM: **Synthesis of new N-benzoxazole and N-benzothiazole derivatives of 3-(4-substituted-phenyl) aminoisoxazol-5(2H)-ones and comparison of their base induced rearrangement.** *J Braz Chem Soc* 2006, **17**:570–576. and references cited therein.
16. Emmons WD: **The preparation and properties of oxaziranes.** *J Am Chem Soc* 1957, **79**:5739–5754.
17. Butler AR, Challis BC, Lobo AM: **Hydrolysis of oxaziridines. Part 3. Evidence for both O- and N-conjugate acid formation with 2,3,3-triethyloxaziridine.** *J Chem Soc Perkin II* 1979:1035–1038.
18. Perrin DD, Armarego WLF, Perrin DR: *Purification of Laboratory Chemicals.* London: Pergamon; 1980.
19. Barton DHR, Blazejewski J-C, Charpiot B, Finet J-P, Motherwell WB, Papoula MTB, Stanforth SP: **Pentavalent organobismuth reagents. Part 3. Phenylation of enols and of enolate and other anions.** *J Chem Soc Perkin Trans I* 1985:2667–2675.
20. Buckle ALJ, McGookin A, Robertson A: **Constituents of "Cortex Piscidiaae Erythrinae." Part II. The synthesis of O-methylpiscidic acid.** *J Chem Soc* 1954:3981–3986.
21. Howk BW, McElvain SM: **The reaction of organic halides with piperidine. II. Certain alpha-bromo-beta-ketonic esters.** *J Am Chem Soc* 1932, **54**:282–289.
22. Logemann H, Almirante L, Caprio L: **Studien in der heterocyclischen reihe, II. Mitteil.: die synthese von 1.3.5-triazinen und 5-oxy-isoxazol-derivaten.** *Chem Ber* 1954, **87**:1175–1179.
23. Kohler EPB, Blatt AHAA: **Diphenyl isoxazolone: a study of the tautomerism of isoxazolones.** *J Am Chem Soc* 1928, **50**:504–515.
24. Teobald BJ: **The Nicholas reaction: the use of dicobalt hexacarbonyl-stabilised propargylic cations in synthesis.** *Tetrahedron* 2002, **58**:4133–4170.
25. Barton DHR, Bolton M, Magnun PD, Marath KG, Poulton GA, West PJ: **Photochemical transformations. Photolysis of thiobenzoic acid O-esters. Photolysis of O-phenethyl thiobenzoates and other thiobenzoates.** *J Chem Soc Perkin Trans* 1973, **1**:1574–1579.

doi:10.1186/1752-153X-7-94

Cite this article as: Gomes et al.: *N-heteroatom substitution effect in 3-aza-cope rearrangements.* *Chemistry Central Journal* 2013 **7**:94.